

Yukon Immunization Program Manual

Section 8 — Biological Products

Influenza Vaccines

September 2026



Table of Contents

Standard Dose, Inactivated Influenza Vaccine (IIV3-SD) FLUZONE®	3
Adjuvanted, Inactivated Influenza Vaccine (AIIV3) FLUAD®	6
Live Attenuated, Influenza Vaccine (LAIV3) FLUMIST®	9

2026/2027 Seasonal Influenza Vaccines (TIV and LAIV)

- **Targets the following strains of influenza (2026 formulation):**

- A/Missouri/11/2025 (H1N1)pdm09-like strain (A/Switzerland/6849/2025, IVR-278)
- A/Darwin/1454/2025 (H3N2)-like strain (A/Michigan/105/2025, SAN-049A)
- B/Tokyo/EIS13-175/2025-like strain (B/Tokyo/EIS13-175/2025, wild type)

Eligibility:

Influenza vaccine should be offered annually to anyone 6 months of age and older who does not have a contraindication to the vaccine.

1. People at higher risk of influenza complications or hospitalization

- All children 6 to 59 months of age
- Adults and children with the following chronic health conditions:
 - Cardiac or pulmonary disorders (includes bronchopulmonary dysplasia, cystic fibrosis, and asthma)
 - Diabetes mellitus and other metabolic diseases
 - Cancer, immune compromising conditions (due to underlying disease, therapy, or both, such as solid organ transplant or hematopoietic stem cell transplant recipients)
 - Renal disease
 - Anemia or hemoglobinopathy
 - Neurologic or neurodevelopmental conditions (includes neuromuscular, neurovascular, neurodegenerative, neurodevelopmental conditions, and seizure disorders [and, for children, includes febrile seizures and isolated developmental delay], but excludes migraines and psychiatric conditions without neurological conditions)
 - Class 3 obesity (defined as body mass index of 40 kg/m² and over)
 - Children 6 months to 18 years of age undergoing treatment for long periods with acetylsalicylic acid, because of the potential increase of Reye's syndrome associated with influenza
- Pregnant women and pregnant individuals
- People of any age who are residents of nursing homes and other chronic care facilities
- Adults 65 years of age and older
- Individuals in or from First Nations, Inuit, or Métis communities as a result of intersecting determinants of health rooted in historic and ongoing colonization and systemic racism

2. People who could transmit influenza to those at high risk

- Health care workers and other care providers in facilities and community settings
- Household contacts, including adults and children, of:
 - Individuals at high risk, regardless of their vaccination status
 - Infants younger than 6 months, who are at high risk but are too young to receive influenza vaccine
 - A household expecting a newborn during the influenza season
- Those providing regular childcare to children 0 to 59 months of age, whether in or out of the home
- Those who provide services within closed or relatively closed settings to people at high risk

3. Other groups

- People who provide essential community services
- Individuals in contact with poultry during avian influenza culling

Available Influenza Vaccines 2026-2027 – Quick Reference Table

Age Group	Recommended Product(s)	Notes
6 to 23 months	FLUZONE®	
2 to 17 years	FLUZONE® , FLUMIST®	FLUMIST® may be offered to healthy children aged 2-17 years without contraindications.
18 to 64 years	FLUZONE®	FLUMIST® may be considered for adults 18 to 59 years with needle phobia. Clients should be advised that this is not the preferred product for their age group. There is evidence that IIV3 may provide better protection than LAIV3 in adults.
65 years and older	FLUAD® preferred	If unavailable or declined, FLUZONE® may be used.

Standard Dose, Inactivated Influenza Vaccine (IIV3-SD)			FLUZONE®
Manufacturer	Sanofi Pasteur Inc.	Biological Classification	Inactivated split virion, trivalent influenza vaccine
Current Formulation	Targets the Influenza virus types A and B (2026-2027 formula).		
INDICATIONS	SCHEDULE		
	6 months to 8 years, no previous influenza vaccination:	• Dose 1: 0.5 mL IM • Dose 2: 0.5 mL IM spaced ≥4 weeks apart	
	6 months to 8 years, previously vaccinated:	1 Dose: 0.5 mL IM	
	9 years of age and older ⓘ	1 Dose: 0.5 mL IM	
	ⓘ FLUAD® influenza vaccine is the preferred product for individuals 65 years and older (see FLUAD® product page).		
BOOSTER DOSES	Annually		
AVAILABLE FORMATS	Multi-dose vial: each vial contains 10 doses of 0.5 mL. Pre-filled syringe: 10 x 0.5 mL single dose syringes without attached needle.		
CONTRAINDICATIONS	• Infants less than 6 months of age. • History of anaphylactic or hypersensitivity reaction to previous influenza vaccine or any component of the vaccine excluding eggs.		
PRECAUTIONS & SPECIAL CONSIDERATIONS	• Delay vaccination in those with severe acute illness; minor illness is not a reason to defer. • History of Severe Oculorespiratory Syndrome (ORS) within 24 hours of receiving influenza vaccine requires YIP consultation. • History of Guillain-Barré Syndrome (GBS) within 6 weeks of a previous influenza vaccine dose requires YIP consultation. • Egg allergy is not a contraindication. People with egg allergies, including those who have experienced anaphylaxis after egg ingestion, can safely receive either		

Standard Dose, Inactivated Influenza Vaccine (IIV3-SD)		FLUZONE®
	inactivated or live attenuated influenza vaccines in any setting where standard vaccine administration practices are followed.	
PREGNANCY AND LACTATION	Data on the use of this vaccine in pregnancy and breastfeeding is limited. However, there is no evidence to suggest a risk to the fetus or the pregnancy from maternal immunization with FLUZONE®. NACI states that influenza vaccination is recommended for pregnant and breastfeeding individuals.	
INTERCHANGEABILITY	For children requiring 2 doses in the same influenza season, it is preferred to use the same product for both doses. If the original product is unavailable or declined, another age-appropriate influenza vaccine may be used.	
RECONSTITUTION AND DILUTION	Do not reconstitute or dilute.	
ADMINISTRATION	• Shake product (multi-dose vial or pre-filled syringe) well prior to administration to ensure uniform suspension. • Inspect for extraneous particulate matter and/or discolouration before use. If these conditions exist, the product should not be administered. • Infants under 12 months of age: IM injection into the anterolateral aspect of the thigh (vastus lateralis). • Individuals 12 months of age and older: IM injection into the deltoid muscle of the upper arm. • Do not inject into the gluteal area or anywhere near major nerves or blood vessels.	
CONCURRENT ADMINISTRATION WITH OTHER VACCINES	NACI states that influenza vaccine may be given at the same time as other vaccines.	
SEROLOGICAL TESTING	Serological testing is not recommended before or after FLUZONE®.	
VACCINE COMPONENTS	Each 0.5 mL dose contains: • 15 µg haemagglutinin (HA) from each of the following strains:	

Standard Dose, Inactivated Influenza Vaccine (IIV3-SD)		FLUZONE®
	○ A/Missouri/11/2025 (H1N1)pdm09-like strain (A/Switzerland/6849/2025, IVR-278) ○ A/Darwin/1454/2025 (H3N2)-like strain (A/Michigan/105/2025, SAN-049A) ○ B/Tokyo/EIS13-175/2025-like strain (B/Tokyo/EIS13-175/2025, wild type) ● Non-medicinal ingredients0.5 mL dose: Phosphate Buffered Saline (sodium chloride 6.51 g/L; sodium phosphate (dibasic anhydrous) 3.83 g/L; sodium phosphate (monobasic anhydrous) 0.410 g/L), Water for Injection quantity sufficient up to 0.5mL ● Preservative: and Triton® X-100 NMT 250 mcg. 0.01% w/v thimerosal is present in the multi-dose presentation only. ● No antibiotics; latex-free.	
APPEARANCE	FLUZONE® is supplied as a clear to slightly opalescent suspension in a vial or prefilled syringe.	
BLOOD/BLOOD PRODUCTS	Does not contain human blood/blood products.	
BOVINE/BOVINE PRODUCTS	Does not contain bovine or porcine products.	
LATEX	Does not contain latex.	
COMMON SIDE EFFECTS	Local: Pain, induration, erythema. Systemic: Headache and myalgia. See product monograph for comprehensive list of potential side effects.	
VACCINE STORAGE & HANDLING	Storage:	
	● Store in refrigerator: 2°C to 8°C. ● Do NOT freeze. ● Store in original packaging, protect from light. ● Between uses, return the multi-dose vial to the recommended storage conditions at 2° to 8°. ● Do not use after the expiration date shown on the label.	
REFERENCES AND RESOURCES		
Canadian Immunization Guide National Advisory Committee on Immunization Product Monograph		

Adjuvanted, Inactivated Influenza Vaccine (IIV3-Adj)			FLUAD®
Manufacturer	Seqirus Canada Inc.	Biological Classification	Influenza vaccine, Surface Antigen, Inactivated, Adjuvanted with MF59C.1
Current Formulation	Targets the Influenza virus types A and B (2026-2027 formula).		
INDICATIONS	SCHEDULE		
	Individuals 65 years and older:	1 Dose: 0.5 mL IM ⓘ	
	ⓘ FLUAD® is the preferred vaccine for this age group. If unavailable or declined, FLUZONE® (or another age-appropriate IIV) may be used.		
BOOSTER DOSES	Annually		
AVAILABLE FORMATS	Single-dose prefilled syringe: 0.5 mL dose		
CONTRAINDICATIONS	- Not authorized for individuals under 65. - History of anaphylactic or hypersensitivity reaction to previous influenza vaccine or any component of the vaccine excluding eggs.		
PRECAUTIONS & SPECIAL CONSIDERATIONS	- Delay vaccination in those with severe acute illness; minor illness is not a reason to defer. - History of Severe Oculorespiratory Syndrome (ORS) within 24 hours of receiving influenza vaccine requires YIP consultation. - History of Guillain-Barré Syndrome (GBS) within 6 weeks of a prior influenza vaccine requires YIP consultation. - Egg allergy is not a contraindication. People with egg allergies, including those who have experienced anaphylaxis after egg ingestion, can safely receive either inactivated or live attenuated influenza vaccines in any setting where standard vaccine administration practices are followed.		
PREGNANCY AND LACTATION	FLUAD® not indicated for populations under 65 years.		

Adjuvanted, Inactivated Influenza Vaccine (IIV3-Adj) FLUAD®	
INTERCHANGEABILITY	FLUAD® is the preferred vaccine for this age group. If unavailable or declined, FLUZONE® (or another age-appropriate IIV) may be used.
RECONSTITUTION AND DILUTION	Do not reconstitute or dilute.
ADMINISTRATION	• Gently shake the contents of each syringe to aid inspection for the presence of particulate matter. After shaking, the normal appearance of FLUAD® is a milky-white suspension. • Do not use the vaccine if particles remain or if product is discoloured. • Individuals 65 years and older: IM injection into the deltoid muscle of the upper arm. • Do not inject into the gluteal area or anywhere near major nerves or blood vessels.
CONCURRENT ADMINISTRATION WITH OTHER VACCINES	FLUAD® may be administered at the same time as other vaccines; use different limbs whenever possible. No minimum interval is required before or after giving another inactivated or live vaccine.
SEROLOGICAL TESTING	Serological testing is not recommended before or after FLUAD®.
VACCINE COMPONENTS	Each prefilled syringe 0.5 mL dose contains: • 15 mcg haemagglutinin surface antigens from each of the following strains: ○ A/Missouri/11/2025 (H1N1) pdm09-like virus ○ A/Darwin/1454/2025 (H3N2)-like virus ○ B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus • Adjuvant (MF59C.1): squalane 9.75 mg, polysorbate 80 1.175 mg, sorbitan trioleate 1.175 mg, sodium citrate 0.66 mg, citric acid 0.04 mg • Other excipients: sodium chloride 4.0 mg, potassium chloride 0.1 mg, calcium chloride dihydrate 0.06 mg, magnesium chloride hexahydrate 0.05 mg, disodium phosphate dihydrate 0.67 mg, potassium dihydrogen phosphate 0.1 mg, water for injection • May contain residual cetyltrimethylammonium bromide (CTAB), formaldehyde, hydrocortisone, kanamycin, neomycin, ovalbumin • No preservatives

Adjuvanted, Inactivated Influenza Vaccine (IIV3-Adj)		FLUAD [®]
APPEARANCE	Milky-white suspension after shaking gently.	
BLOOD/ BLOOD PRODUCTS	Does not contain blood or blood products.	
BOVINE/ PORCINE PRODUCTS	Does not contain bovine or porcine products.	
LATEX	Does not contain latex.	
COMMON SIDE EFFECTS	• Local: pain, redness, swelling at injection site. • Systemic: headache, fatigue, malaise, muscle pain, joint pain, shivering, sweating, and warmth.	
STORAGE & HANDLING	• Store in refrigerator: 2°C to 8°C. • Do NOT freeze. • Store in original packaging, protect from light. • May be used up to the expiry date on the carton/syringe label.	
REFERENCES AND RESOURCES		
Canadian Immunization Guide		
National Advisory Committee on Immunization		
Product Monograph		

Live Attenuated, Influenza Vaccine (LAIV3)				FLUMIST®
Manufacturer	AstraZeneca Canada		Biological Classification	Influenza vaccine (live, attenuated)
Current Formulation	Targets the Influenza virus types A and B (2026-2027 formula).			
INDICATIONS	SCHEDULE			
	Children 2 to 8 years, not previously vaccinated with seasonal influenza vaccine		• Dose 1: 0.2 mL intranasal (0.1 mL/nostril) • Dose 2: 0.2 mL intranasal (0.1 mL/nostril), spaced ≥4 weeks apart	
	Children 2 to 8 years, previously vaccinated with seasonal influenza vaccine		1 Dose: 0.2 mL intranasal (0.1 mL/nostril)	
	Individuals 9 to 17 years		1 Dose: 0.2 mL intranasal (0.1 mL/nostril)	
	Adults 18 to 59 years with severe needle phobia		1 Dose: 0.2 mL intranasal (0.1 mL/nostril) ⓘ	
	ⓘ Adults 18 to 59 years of age receiving FLUMIST® due to severe needle phobia should be advised that this is not the preferred product for their age group. There is evidence that IIV3 may provide better protection than LAIV3 in adults.			
	BOOSTER DOSES	Annually		
AVAILABLE FORMATS	Prefilled single-use sprayer: 0.2 mL dose (0.1 mL per nostril)			

Live Attenuated, Influenza Vaccine (LAIV3) FLUMIST®	
CONTRAINDICATIONS	• Not indicated for individuals younger than 2 years of age. • History of anaphylactic or hypersensitivity reaction to previous influenza vaccine or any component of the vaccine excluding eggs. • Severe asthma (requiring high dose inhaled or oral corticosteroids) or active wheezing (medically attended in the 7 days prior). • Immunocompromised individuals. • Pregnant individuals. • Children and adolescents (2 to 17 years) receiving aspirin-containing therapy (due to association with Reye's syndrome); avoid aspirin-containing products for 4 weeks after receipt.
PRECAUTIONS & SPECIAL CONSIDERATIONS	• LAIV should not be administered until 48 hours after antiviral agents active against influenza (e.g. oseltamivir, zanamivir) are stopped. Furthermore, those antiviral agents, if administered within 2 weeks after receipt of LAIV, may inactivate the replicating vaccine virus and reduce its immunogenicity. • If significant nasal congestion is present that might impede delivery of LAIV to the nasopharyngeal mucosa, IIV can be administered or LAIV can be deferred until resolution of congestion. • Delay vaccination in those with severe acute illness; minor illness is not a reason to defer. • Vaccine recipients should avoid close contact with severely immunocompromised individuals (e.g., bone marrow transplant recipients in isolation) for 2 weeks after vaccination due to risk of transmission of live attenuated virus. • Health care workers in close contact with people with medical conditions or treatment that weaken the immune system. • History of Severe Oculorespiratory Syndrome (ORS) within 24 hours of receiving influenza vaccine requires YIP consultation. • History of Guillain-Barré Syndrome (GBS) within 6 weeks of a prior influenza vaccine requires YIP consultation. • Egg allergy is not a contraindication. People with egg allergies, including those who have experienced anaphylaxis after egg ingestion, can safely receive either inactivated or live attenuated influenza vaccines in any setting where standard vaccine administration practices are followed.
PREGNANCY AND LACTATION	Not indicated; no data available.

Live Attenuated, Influenza Vaccine (LAIV3) FLUMIST®	
INTERCHANGEABILITY	For children requiring 2 doses in the same influenza season, it is preferred to use the same product for both doses. If the original product is unavailable or declined, another age-appropriate inactivated influenza vaccine may be used.
RECONSTITUTION AND DILUTION	Do not reconstitute or dilute.
ADMINISTRATION	- Administer 0.2 mL intranasally (0.1 mL into each nostril). Do not inject. Administration steps: - Remove the rubber tip protector. Do not remove the dose-divider clip at the other end of the sprayer. - With the recipient sitting upright, place tip of the sprayer just inside a nostril to ensure vaccine is delivered into the nose. - In one motion depress the plunger as rapidly as possible until the dose-divider clip prevents you from going further. - Pinch and remove the dose divider clip from the plunger. - Place the tip of the sprayer just inside the other nostril and with a single motion depress the plunger as rapidly as possible to deliver the rest of the vaccine.
CONCURRENT ADMINISTRATION WITH OTHER VACCINES	FLUMIST® may be administered at the same time as other vaccines; use different injection sites. No minimum interval is required before or after giving another inactivated or live vaccine.
SEROLOGICAL TESTING	Serological testing is not recommended before or after FLUMIST®
VACCINE COMPONENTS	Fluorescent focus units of live attenuated influenza virus reassortants of each of the following strains: - A/Missouri/11/2025 (H1N1) pdm09-like virus - A/Darwin/1454/2025 (H3N2)-like virus - B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus Non-medical Ingredients: arginine hydrochloride, dibasic potassium phosphate, gelatin hydrolysate (porcine Type A), monobasic potassium phosphate, monosodium glutamate, sucrose

Live Attenuated, Influenza Vaccine (LAIV3)		FLUMIST [®]
	• May contain residual: gentamicin, ovalbumin • No preservatives	
APPEARANCE	Colourless to pale yellow, clear to opalescent suspension; small white particles may be present.	
BLOOD/BLOOD PRODUCTS	Does not contain blood products.	
BOVINE/BOVINE PRODUCTS	Contains gelatin hydrolysate (porcine Type A).	
LATEX	Does not contain latex.	
EXPECTED REACTIONS	• Local: runny nose or nasal congestion. • Systemic: decreased appetite, weakness, headache, fever, sore throat, cough	
STORAGE AND HANDLING	Storage:	
	• Store in refrigerator: 2°C to 8°C. • Do NOT freeze. • Store in original packaging, protect from light. • The shelf life of FLUMIST[®] is shorter than that of inactivated influenza vaccines; always check the expiry date on the sprayer label. • A single excursion to room temperature (≤25 °C) for up to 12 hours is permitted; return to refrigerated storage immediately afterward.	
	Handling:	
	• Do not use if the sprayer has been frozen. • Use as supplied; do not shake. • Administer 0.2 mL intranasally (0.1 mL per nostril) using the prefilled sprayer. • Dispose of sprayer after single use.	
RESOURCES & REFERENCES		
National Advisory Committee on Immunization Statements Canadian Immunization Guide Product Monograph		